Gibson Dunn Advises BVF Partners L.P. on up to $400 Million Financing for Immunic, Inc.

Firm News  |  February 25, 2026

---

Gibson Dunn represented BVF Partners L.P. as lead investor in the up to $400 million private placement financing for Immunic, Inc., a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases.

Gibson Dunn regularly advises life sciences investors on large-scale private placement financings for biotechnology companies.

The Gibson Dunn team included Ryan Murr, Branden Berns, Karen Spindler, Nick Linke, and Lauren Romagnoli.